Eli Lilly & Co. has reported that Zepbound, its weight-loss drug, has performed better than Wegovy, a medication from Novo Nordisk A/S, in the first direct comparison trial between the two drugs.
In a study sponsored by Lilly, participants who took Zepbound lost an average of 20% of their body weight, which is approximately 50 pounds, over a period of 72 weeks.
On the other hand, those who received Wegovy lost an average of 14% of their body weight. These results support previous trials that indicated Zepbound has a more significant impact on weight loss compared to its competitor.